Table 2.
Cumulative Benzodiazepine Exposure During the Study Baseline Exposure Period by Medication Type*
| Medication | Patients With Benzodiazepine Use (N = 150 282) N (%) |
Total Benzodiazepine Exposure Person-Days (N = 271 625 248) N (%) |
|---|---|---|
| Short-acting † | ||
| Lorazepam | 53 464 (35.6) | 58 543 918 (21.6) |
| Temazepam | 50 910 (33.9) | 30 421 821 (11.2) |
| Clonazepam | 31 094 (20.7) | 81 344 862 (29.9) |
| Alprazolam | 30 315 (20.2) | 62 472 212 (23.0) |
| Oxazepam | 8 917 (5.9) | 7 276 693 (2.7) |
| Triazolam | 734 (0.5) | 262 178 (0.1) |
| Estazolam | 4 (0.0) | 539 (0.0) |
| Long-acting | ||
| Diazepam | 32 360 (21.5) | 25 861 540 (9.5) |
| Chlordiazepoxide | 4 138 (2.8) | 3 753 102 (1.4) |
| Clorazepate | 895 (0.6) | 1 219 814 (0.4) |
| Flurazepam | 662 (0.4) | 689 124 (0.3) |
| Halazepam | 1 (0.0) | 420 (0.0) |
| Prazepam | 4 (0.0) | 106 (0.0) |
*Column percentages do not sum to 100% because patients could receive >1 benzodiazepine during the exposure period.
†Benzodiazepines are classified as short- or long-acting by half-life (ie, time taken for blood concentration to fall to half its peak value) (20).